Welcome to our dedicated page for Unicycive Therapeutics news (Ticker: UNCY), a resource for investors and traders seeking the latest updates and insights on Unicycive Therapeutics stock.
Unicycive Therapeutics Inc (UNCY) is a clinical-stage biotechnology company pioneering novel treatments for kidney diseases, including hyperphosphatemia and acute kidney injury. This page aggregates all corporate announcements, regulatory updates, and research milestones related to its innovative pipeline.
Investors and healthcare professionals will find timely updates on clinical trial progress, partnership developments, and financial disclosures. Our curated collection includes press releases about Renazorb (phosphate-binding therapy) and UNI-494 (acute kidney injury treatment), along with strategic business decisions impacting the company's trajectory.
Key content categories include FDA communications, peer-reviewed study publications, intellectual property updates, and earnings reports. All materials are sourced directly from official company channels to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to UNC's latest developments in renal therapeutics. Regularly updated to reflect new breakthroughs in drug development and corporate strategy, it serves as an essential resource for monitoring this innovative biotech's progress.
Unicycive Therapeutics (Nasdaq: UNCY) reported its Q1 2024 financial results and provided a business update.
The pivotal clinical trial for its lead asset, oxylanthanum carbonate (OLC), is on track with topline data expected in Q2 2024. Additionally, OLC and UNI-494 will be featured in multiple presentations at upcoming nephrology conferences. The company has completed enrollment in the pivotal OLC trial. UNI-494, aimed at preventing delayed graft function in kidney transplant patients, has progressed through the multiple ascending dose portion of Phase 1 trials with results expected later this year.
Unicycive was granted orphan drug designation for UNI-494 by the FDA, providing potential benefits such as tax credits and market exclusivity. The company completed a $50 million private placement, bolstering its cash position to $48.9 million as of March 31, 2024. However, the company reported a net loss of $21.2 million for Q1 2024, primarily due to increased R&D and administrative expenses.
FAQ
What is the current stock price of Unicycive Therapeutics (UNCY)?
What is the market cap of Unicycive Therapeutics (UNCY)?
